Brief: Adc Therapeutics Announces Completion Of Enrollment Of Phase 3 Confirmatory Clinical Trial Of Zynlonta In Combination With Rituximab In 2L+ Diffuse Large B-Cell Lymphoma
30/12/2024 21:51
Dec 30 (Reuters) - ADC Therapeutics SA ADCT.N :
* ADC THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT OF
PHASE 3
CONFIRMATORY CLINICAL TRIAL OF ZYNLONTA® IN COMBINATION WITH
RITUXIMAB IN 2L+ DIFFUSE LARGE B-CELL LYMPHOMA
Source text: ID:nPn4FzrXCa
Further company coverage: ADCT.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adc Therapeutics
See all newsBrief: Adc Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements
ADC Therapeutics SA reports results for the quarter ended June 30 - Earnings Summary
ADC Therapeutics Q2 loss narrows; cuts 17% workforce
ADC Therapeutics SA expected to post a loss of 21 cents a share - Earnings Preview
ADC Therapeutics SA expected to post a loss of 21 cents a share - Earnings Preview